Automated CAR-T therapy shows promise for Tough-to-Treat lymphoma

NCT ID NCT07606937

Recruiting now Disease control Sponsor: Shenzhen Fosun Kairos Biotechnology Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing a CAR-T cell therapy made using an automated process for people with relapsed or refractory large B-cell lymphoma. The study will enroll 12 adults whose cancer has not responded to or returned after first-line treatment. Researchers will measure how many patients achieve remission and track side effects to see if this manufacturing method is safe and effective.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: axicabtagene ciloleucel (CAR-T cell therapy)
What this could lead to: If successful, this could offer a new, more consistent way to produce CAR-T cells for treating aggressive lymphoma that has returned after initial therapy.
What could go wrong: This is a very early phase 1 trial with only 12 participants, so results may not apply broadly. CAR-T therapy can cause serious side effects like cytokine release syndrome and neurological problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma Recurrence relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA

Contacts and locations

Locations

Beijing Cancer Hospital
NOT_YET_RECRUITING

Beijing, Beijing Municipality, 100142, China
Shanghai Jiaotong University School of Medicine Ruijin Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200025, China
Sun Yat-sen University Cancer Center
NOT_YET_RECRUITING

Guangzhou, Guangdong, 510700, China
The Frist Affiliated Hospital of Soochow University
NOT_YET_RECRUITING

Suzhou, Jiangsu, 215006, China
Tianjin Medical University Cancer Institute & Hospital
RECRUITING

Tianjin, Tianjin Municipality, 300000, China
West China Hospotal Sichuan University
RECRUITING

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.